Amgen slips on eczema drug results
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- Amgen stock dipped early after producing results from two recent drug studies.
- A drug that treats atopic dermatitis appeared less useful compared with Sanofi's current drug.
- Dow Jones sinks despite US housing stats showing better than expected New Home Sales.
- Positive results also followed Phase 3 trial of Uplizna.
Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results of several drug trials.
The Dow Jones Industrial Average (DJIA), of which Amgen is a member, fell 0.4% against a backdrop of an improving NASDAQ. The DJIA has been wobbly all week.
US housing data early in the session showed that mortgage applications were rising. Additionally, New Home Sales in the US fell 4.7% MoM but were not as bad as expected.
Amgen stock news
Amgen released results from two studies late Tuesday after the market close, both of which proved positive.
First, its Phase 3 trial for Uplizna, a drug that treats IgG4-type diseases, showed an 87% reduction in IgG4-RD flare-ups. It also met all three secondary endpoints. Uplizna has been approved for treating neuromyelitis optica spectrum disorder.
Second, its Phase 3 study of rocatinlimab, which treats atopic dermatitis, was statistically significant. Following 24 weeks of treatment, nearly 33% of patients saw at least a 75% improvement in the severity of eczema.
However, this last study was the negative issue for investors. The Sanofi-created and Regeneron-marketed Dupixent drug, which is focused on the same use case, achieved figures of 51% and 44% during its two Phase 3 studies compared with Amgen’s 33%. Hence, Amgen’s drug works but not quite as well as that of its competitors.
In reporting by industry website Fierce Biotech, Amgen Executive Vice President Murdo Gordon was not dissuaded. Gordon said that more than one drug was needed to meet the needs of patients in the atopic dermatitis market and that Amgen’s data suggested that doctors often switch prescriptions early on in treatment. Rocatinlimab’s use of a different mechanism for treatment might also persuade some physicians, according to Gordon.
Amgen stock forecast
Amgen stock is up 9.5% year to date and 24% over the past year despite dropping to $315 on Wednesday. Seeing as the pharma stock slid easily below the 100-day Simple Moving Average (SMA) on Wednesday, it could be foolish to think that the 200-day SMA might hold, which is now near $302.
If it fails to hold, then traders will look to $296, which held up earlier this summer. Below there is resistance turned support at $260, which was treated with respect throughout 2023. However, a break back above $320 would put an end to bearish sentiment.
AMGN daily stock chart
- Amgen stock dipped early after producing results from two recent drug studies.
- A drug that treats atopic dermatitis appeared less useful compared with Sanofi's current drug.
- Dow Jones sinks despite US housing stats showing better than expected New Home Sales.
- Positive results also followed Phase 3 trial of Uplizna.
Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results of several drug trials.
The Dow Jones Industrial Average (DJIA), of which Amgen is a member, fell 0.4% against a backdrop of an improving NASDAQ. The DJIA has been wobbly all week.
US housing data early in the session showed that mortgage applications were rising. Additionally, New Home Sales in the US fell 4.7% MoM but were not as bad as expected.
Amgen stock news
Amgen released results from two studies late Tuesday after the market close, both of which proved positive.
First, its Phase 3 trial for Uplizna, a drug that treats IgG4-type diseases, showed an 87% reduction in IgG4-RD flare-ups. It also met all three secondary endpoints. Uplizna has been approved for treating neuromyelitis optica spectrum disorder.
Second, its Phase 3 study of rocatinlimab, which treats atopic dermatitis, was statistically significant. Following 24 weeks of treatment, nearly 33% of patients saw at least a 75% improvement in the severity of eczema.
However, this last study was the negative issue for investors. The Sanofi-created and Regeneron-marketed Dupixent drug, which is focused on the same use case, achieved figures of 51% and 44% during its two Phase 3 studies compared with Amgen’s 33%. Hence, Amgen’s drug works but not quite as well as that of its competitors.
In reporting by industry website Fierce Biotech, Amgen Executive Vice President Murdo Gordon was not dissuaded. Gordon said that more than one drug was needed to meet the needs of patients in the atopic dermatitis market and that Amgen’s data suggested that doctors often switch prescriptions early on in treatment. Rocatinlimab’s use of a different mechanism for treatment might also persuade some physicians, according to Gordon.
Amgen stock forecast
Amgen stock is up 9.5% year to date and 24% over the past year despite dropping to $315 on Wednesday. Seeing as the pharma stock slid easily below the 100-day Simple Moving Average (SMA) on Wednesday, it could be foolish to think that the 200-day SMA might hold, which is now near $302.
If it fails to hold, then traders will look to $296, which held up earlier this summer. Below there is resistance turned support at $260, which was treated with respect throughout 2023. However, a break back above $320 would put an end to bearish sentiment.
AMGN daily stock chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.